Furiex Makes Inroads In Tough-To-Treat IBS-d With Positive Phase III Eluxadoline Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Eluxadoline met endpoints in two Phase III studies, positioning the drug for submission in a sparsely served therapeutic area, with only one FDA-approved drug and millions of patients in the U.S. and EU. Mild pancreatitis was reported in a handful of patients, but is manageable, company says.
You may also be interested in...
Irritable Bowel Drugs From Salix, Actavis Await FDA Action In 2015
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.
Forest Keeps Wheeling And Dealing Ahead Of Merger
Acquisitions boosted Forest’s 2014 sales, and the company isn’t slowing down its acquisition strategy even though it is working toward a merger with Actavis.
J.P. Morgan Notebook: Thursday, January 16
News and notes from the fourth and final day of the 2014 J.P. Morgan Healthcare Conference, including highlights from Furiex Pharmaceuticals’ late-stage pipeline, GSK’s latest DPU, newly public Intrexon, and angel-backed KemPharm.